



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Pharmaceutical and Therapeutics (P & T) Committee Meeting June 14, 2012

Location: **Iowa State Capitol Room 116
1007 E. Grand Avenue
Des Moines, IA 50319**

Time: 9:30 a.m. – 4:30 p.m.

Tentative Agenda

1. Welcome & Introductions
 - a) Committee Members and Staff
 - b) Approval of the minutes
2. Update
 - a) Preferred Drug List (PDL)
 - b) Medicaid Drug Rebate Issues
 - c) Prior Authorization Criteria/Pro-DUR edits
 - d) Legislation
 - e) IME Updates
3. Public Comment (**See attachment 1 for Conflict of Interest Disclosure**)
4. Closed Executive Session
 - a. Economic Review of the Iowa Medicaid Preferred Drug List, Newly Released Drugs, Newly Released Generic Drugs, New Dosage Forms, and Contracts
 - b. Review and discussion of the Confidential Public Comments
5. Preferred Drug List (PDL) discussion and deliberation
(See attachment 2 for order of discussion)
6. Final Recommendations by the P & T Committee on the Iowa Medicaid Preferred Drug List
7. Review of Newly Released Drugs by GHS
(See attachment 3 for order of discussion)
8. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)
9. Review of Newly Released Generic Drugs, Dosage Forms or Strengths by GHS
(See attachment 4 for order of discussion)
10. Final Recommendations by the P & T Committee on Newly Released Generic Drugs, Dosage Forms or Strengths
11. Preview of next meeting.

****Disclaimer: Executive Sessions may be necessary during the deliberation process****

www.IowaMedicaidPDL.com

Next scheduled meeting is September 13, 2012

For more information contact Erin Halverson at ehalver@dhs.state.ia.us or (515) 974-3126

Attachment 1

Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee

Speaker Conflict of Interest Disclosure

The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons speaking or presenting to the Iowa Medicaid P&T Committee are asked to disclose any financial or other affiliation with organizations that may have a direct or indirect interest in the business in front of the Committee. Those persons speaking or presenting at the P&T Committee meetings are asked to disclose potential conflicts on this form. P&T Committee members disclose potential conflicts each year on a separate form.

A financial interest may include, but is not limited to, being a shareholder in the organization, being on retainer with the organization, having research or honoraria paid by the organization, or receiving other forms of remuneration from an organization. An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such a financial relationships or affiliation does not necessarily constitute a conflict of interest and will not preclude an individual from participating or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Your responses below will be read out loud before your presentation to the P&T Committee.

Please check the box of the statement that best applies.

Statement of No Conflicts

I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.

Disclosures

I have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee

I refuse to state my affiliations

Organization (List additional on the back of the form.)	Role/Relationship (List additional on the back of the form.)

_____ (print name)

_____ (signature) (date)

Attachment 2

Iowa Medicaid Preferred Drug List

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Removed belladonna & opium suppositories from the PDL as they do not meet the definition of a covered drug.
2. Recommend to change Advate to recommended to maximize cost savings to the program.
3. Recommend to change butisol to non-preferred for diagnosis and treatment duration verification.
4. Recommend to change legend polyethylene glycol to preferred to maximize cost savings to the program.
5. Recommend to change Seroquel to non-preferred to maximize cost savings to the program (quetiapine is preferred).
6. Recommend to change triazolam to non-preferred with conditions as a recommendation from the DUR Commission.

Attachment 3
Newly Released Drugs

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Erivedge- Recommend status on the PDL as Non-Recommended
2. Inlyta- Recommend status on the PDL as Non-Recommended
3. Kalydeco- Recommend status on the PDL as Non-Preferred
4. Picato- Recommend status on the PDL as Non-Preferred
5. Zioptan- Recommend status on the PDL as Non-Preferred

Attachment 4

Newly Released Generic Drugs, New Dosage Forms, New Drug Names, and New drug Strengths

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

NEWLY RELEASED GENERIC DRUGS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Escitalopram	Lexapro / Preferred	Non-Preferred
Fluocinolone Acetonide Oil	Dermotic / Non-Preferred	Non-Preferred
Ibandronate	Boniva / Non-Preferred	Non-Preferred
Irbesartan	Avapro / Preferred with Conditions	Non-Preferred with Conditions
Irbesartan/HCTZ	Avalide / Preferred with Conditions	Non-Preferred with Conditions
Lamivudine/Zidovudine	Combivir / Recommended	Non-Recommended
Methylphenidate ER Capsule	Ritalin LA / Non-Preferred with Conditions	Non-Preferred with Conditions
Modafinil	Provigil / Preferred with Conditions	Non-Preferred with Conditions
Progesterone Capsule	Prometrium / Non-Preferred	Non-Preferred
Quetiapine	Seroquel / Non-Preferred	Preferred
Ziprasidone	Geodon / Preferred	Non-Preferred

NEW DRUG DOSAGE FORMS		
Bydureon	Byetta / Preferred with Conditions	Non-Preferred with Conditions
Intermezzo	Zolpidem / Preferred with Conditions	Non-Preferred with Conditions
Janumet XR	Janumet / Non-Preferred with Conditions	Non-Preferred with Conditions
Oxecta	Oxycodone / Preferred	Non-Preferred with Conditions

NEW DRUG NAMES / COMBINATIONS

Dutoprol	Metoprolol Succinate ER/ Preferred HCTZ / Preferred	Non-Preferred
Edarbyclor	Edarbi / Non-Preferred with Conditions Chlorthalidone / Preferred	Non-Preferred with Conditions
Gammaked	Gamunex / Preferred	Non-Preferred
Jentadueto	Tradjenta / Preferred with Conditions Metformin / Preferred	Non-Preferred with Conditions